Lowell Segal

Lowell Segal

Partner

Life Sciences Expertise

Lowell represents pharmaceutical, biotechnology, medical device, and other technology-based companies in a wide range of strategic transactions and corporate matters. He also represents VC firms in their portfolio company investments, primarily in the life sciences and IT industries.
Broad Transactional Experience

He advises on a variety of transactions, including collaborations, technology licensing matters, spin-outs, divestitures, asset purchases, R&D projects, and supply, manufacturing, and distribution arrangements.

Lowell Segal is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the firm's life sciences practice. He represents pharmaceutical, biotechnology, medical device, and other technology-based companies in a wide range of strategic transactions and corporate matters, including collaborations; technology licensing; spin-outs; divestitures; asset purchases; research and development projects; supply, manufacturing, and distribution arrangements; and venture capital financings. He also represents venture capital firms in their portfolio company investments, primarily in the life sciences and information technology sectors.

Prior to rejoining the firm in 2016, Lowell was a partner in the life sciences practice at Ropes & Gray.

Experience

Prior to rejoining the firm in 2016, Lowell was a partner in the life sciences practice at Ropes & Gray.

Education

J.D., Harvard Law School, 2000
M.A., Stanford University, 1996
B.S., Stanford University, 1996

Honors

Selected for inclusion in the 2015 edition of The Legal 500 US

Admissions

State Bar of California

Credentials

Education

J.D., Harvard Law School, 2000
M.A., Stanford University, 1996
B.S., Stanford University, 1996

Honors

Selected for inclusion in the 2015 edition of The Legal 500 US

Admissions

State Bar of California

Recent Insights

Client Highlights

On October 17, 2023, Gilead Sciences and Assembly Biosciences, a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, announced that they have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). Wilson Sonsini Goodrich & Rosati advised Assembly Bio on the transaction.

Assembly Bio’s current portfolio of small molecule antiviral therapeutics includes both clinical and preclinical programs, including next-generation core inhibitor ABI-4334 for the treatment of HBV, long-acting helicase-primase inhibitor ABI-5366 for herpes simplex virus (HSV), an orally bioavailable HDV entry inhibitor ABI-6250, and a pan-herpes polymerase inhibitor program.

Learn More

Client Highlights

On June 30, 2022, Novartis announced that it acquired Kedalion Therapeutics and its AcuStream technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. Wilson Sonsini Goodrich & Rosati advised Kedalion on the transaction.

Kedalion is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, California. In November 2021, Kedalion Therapeutics announced the completion of its Series B financing led by Novartis, which included an exclusive option to acquire the company and its AcuStream technology.

Learn More